BIOXYTRAN, INC Uncategorized Contracts & Agreements
12 Contracts & Agreements
- Extract from Valuation Report of NDPD Pharma, dated October 1, 2024 (Filed With SEC on October 29, 2024)
- Form of Option Agreement dated June 4, 2021 (Filed With SEC on November 3, 2023)
- Form of Closing Agreement with TRITON FUNDS LP, dated September 18, 2023 (Filed With SEC on September 19, 2023)
- Amendment to Closing Agreement with TRITON FUNDS LP, dated August 2, 2023 (Filed With SEC on August 3, 2023)
- Form of Closing Agreement with Triton Funds LLC, dated June 8, 2023 (Filed With SEC on June 12, 2023)
- Amendment to engagement letter with WallachBeth Capital LLC, dated May 8, 2023 (Filed With SEC on June 12, 2023)
- Approval of International Patent WO2022/099052 - Polysaccharides for Use in Treating Sars-Cov-2 Infections, dated May 12, 2022 (Filed With SEC on June 10, 2022)
- Form of Private Placement Memorandum dated September 17, 2021 (Filed With SEC on November 17, 2021)
- Form of Private Placement Memorandum dated February 26, 2021 (Filed With SEC on November 17, 2021)
- Form of Subsidiary Option dated June 4, 2021 (Filed With SEC on November 17, 2021)
- Investor Relations Agreement between Bioxytran, Inc. and Resources Unlimited NW LLC. dated April 22, 2019 (Filed With SEC on April 26, 2019)
- Form of Agreement of Accord and Satisfaction between U.S. Rare Earth Minerals, Inc., and creditor, dated September 17, 2018 (Filed With SEC on September 24, 2018)
